Work

Viagenpumatucel-L (HS-110) plus nivolumab in patients with advanced non-small cell lung cancer (NSCLC) after checkpoint inhibitor treatment failure.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.9109

Authors: Daniel Morgensztern, Rachel E. Sanborn, Lyudmila Bazhenova, Saiama Naheed Waqar, Lori McDermott, Jeff Hutchins, David L. Rimm, Luis E. Raez, Corey J. Langer, Roger B. Cohen

Institutions: Washington University in St. Louis, Providence Portland Medical Center, University of California San Diego, Heat Biologics (United States), Yale University, Florida International University, University of Pennsylvania

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2946955088

Cites:

Cited by: 5

Related to: 10